This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

HQK-1001

HemaQuest Pharmaceuticals, Inc.

Drug Names(s): HQK-1001

Description: HQK-1001 is an orally administered short chain fatty acid (SCFA) derivative, which has a unique combination of biological effects - induction of fetal globin and stimulation of red blood cell production - that addresses the underlying pathological mechanisms in sickle cell disease and a related disorder, beta thalassemia. HQK-1001 increases fetal globin through displacement of a repressor complex from the gamma globin gene promoter.

Deal Structure: HemaQuest obtained an exclusive worldwide license for a series of patents and patent applications for HQK-1001 from Boston University.


HQK-1001 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug